Evidence and desperation in off-label prescribing: recombinant factor VIIa
Access status:
Open Access
Type
ArticleAbstract
Wendy Lipworth and colleagues explore why clinicians prescribe recombinant f actor VIIa off-label for major haemorrhage, despite a lack of supporting evidence—and why this mattersWendy Lipworth and colleagues explore why clinicians prescribe recombinant f actor VIIa off-label for major haemorrhage, despite a lack of supporting evidence—and why this matters
See less
See less
Date
2012-01-01Publisher
BMJLicence
Creative Commons Attribution Licence CC BY-NC 3.0Citation
Lipworth W, Kerridge I, Little JM, Day R. Evidence and desperation in off-label prescribing: recombinant factor VIIa. BMJ 2012;344:d7926Share